Search Weight Loss Topics:

Page 826«..1020..825826827828..840850..»

Behavioural Change: Why a letter in the post won’t work – Business Leader

Posted: April 20, 2020 at 9:51 pm

Written by Roger Philby, CEO of The Chemistry Group

Over the past couple of weeks, households across the UK received a letter from the Government outlining important COVID-19 health advice, including rules on leaving the house and social distancing. Yet I can say with confidence that such a letter will fail to elicit any form of meaningful change in the publics behaviour towards minimising the spread of the virus.

A letter in the post will not change behaviour because knowledge is not behaviour. If it were, we wouldnt speed, smoke or fail to keep a 2m social distance from each other when we know that these things are bad for us and everyone around us.

In my time at The Chemistry Group, we have helped many companies create effective organisational change, and in the process have identified some key principles that will be useful for people undergoing the fairly major, enforced changes that are our current reality. These principles will not only help now but will also be vital for those determined to emerge from the current crisis stronger and more successful than before.

Firstly, let me rewind to why and how we developed these principles.

Chemistry has just finished a big piece of insight work for an FTSE 100 multinational organisation. The client was worried that with a huge change of context (post-financial crash) salespeople were struggling with new ways of working

Anticipating this the client had put their 150 managers through rigorous and extensive management training. Chemistrys data clearly showed that most of the managers had the Intellect, Personality, Motivation and Experience to succeed, they just werent. The problem was that the organisation had conflated knowledge with behaviour.

This organisation needed to focus on three behaviours to turn around its revenue gap, only three:

When the client challenged us to help them implement these behaviours, we started gathering information, looking for data-driven insights. What was out there in the world of training/learning & development could help initiate scale behavioural change?

It turns out weight loss is a perfect analogy for what is wrong with training in organisations. Like all of us that have struggled to lose weight, these sales managers knew what to do, they just didnt do it. I know I need to exercise and run a calorie deficit, I even know what to eat and what exercises to doI just dont do it? Why not? Because I dont have time, because I have other pressing things to do, because, because, because. How many times have you run those kinds of thoughts through your head at home and at work? If you are anything like me, too many to count.

Within three weeks we had studied Weight Watchers and Alcoholics Anonymous and within six weeks we had a behavioural change methodology that scaled across an organisation of 1,000+ people. We have illustrated three of them below:

Do one thing at a time, get great at it, be consistent, then do the next thing. In the above example, we worked on one behaviour for 3 months and only when we hit a level of consistency did we introduce the next behaviour.

Finally, focus on managers of people. For our client, just 150 managers caused a wave of behavioural change that turned around an organisations fortunes. 7% behind their target in February, the organisation ended up beating it by 14%, achieving the market-leading position for the first time in 8 years and receiving industry-wide accolades.

Make the behavioural change in groups, at Chemistry we call them Pods. There is a reason all WW classes and AA meetings are groups of people. Behavioural change is hard, you need support from people who are all going through the same change.

Not only does instituting the change in a group encourage support it also adds motivation. Whether people lack rigorous self-discipline or have a competitive streak that means they perform best against others, a group dynamic can motivate people to adopt the behaviours they know they should more quickly, and more effectively.

Behavioural change has to be led by one of the cohort going through the change, not an expert. The person leading the WW class was often not the kind of fitness influencer we see plastered all over social media, thats the point. Managers are far more likely to listen to one of their peers who has achieved the change they are trying to make and accept candid feedback from this person.

Having a peer in the behavioural change process is also likely to result in more effective and accurate feedback, as they will have a more in-depth and immediate experience of the context and process, rather than just a finished idea of what the end result should look like.

See the rest here:
Behavioural Change: Why a letter in the post won't work - Business Leader

3 Out of the Box First Round Choices To Improve The Packers – Total Packers

Posted: April 20, 2020 at 9:51 pm

What If They dont take The Obvious Receiver?

Every Packer Fan is praying for Rodgers to have another weapon in the passing game. The 2020 draft class might be so deep in wide receiver that the Packers could wait to find LaFleurs new tool. So if the Packers skip on a wide receiver in the first round, who should they target?

Feb 28, 2020; Indianapolis, Indiana, USA; Wisconsin Badgers running back Jonathan Taylor (RB27) participates in a workout drill during the 2020 NFL Combine at Lucas Oil Stadium. Brian Spurlock-USA TODAY Sports

College: University of Wisconsin

Year: Junior

Over Taylors three years in Madison, he ran for over 6,000 yards and averaged almost seven yards per carry. He is one of the fastest running backs in this draft class, clocking a 4.4 40-yard dash time. Taylor is a durable and quick back that can add some juice for the Green Bay backfield coming in when Aaron Jones needs a rest.

Taylor would fit in the passing part of Green Bays offense on all downs eventually. Even though he only had a little over 400 receiving yards in college, he started to show his true receiving skills in his final year as a Badger. Coach LaFleur will be able to recognize how elusive he is when he gets into the open field and how hard it is to bring him down when the ball is in his hands. I can see the Packers splitting him out as a slot receiver and have him run mesh routes on critical downs. He can also be valuable running smash routes, curls, and screens out of the backfield. Jonathan Taylor could thrive in this offense because Lafleur always keeps his running backs active and Rodgers is always best finding a running back on a checkdown letting them make a play in the open field.

Aaron Jones rookie contract will expire after this years season, as well as Jamaal Williams. Jones will most likely be re-signed after this years season proving to be the franchise back. The only question that makes this decision hard is veterans, Kenny Clark, Corey Linsley, and Kevin Kings contracts will expire too.

The Packers could go a different route and re-sign Pro Bowler Kenny Clark and veteran Center Corey Linsley, while also giving the same opportunity to Kevin King(5 INT last season). This would mean that they would have to let Jones walk. Jones will become an expensive target for teams, and if Green Bay doesnt want to go the expensive route, they have to start looking for the future and heavily consider taking a shot at Jonathan Taylor. Even if Aaron Jones does re-sign long term, Taylor could be a great aspect to the offense opening up new challenges for opposing defenses.

Wisconsin Alumni already making him a fan favorite

Able to make a play when the play is already busted (Comparison= Saquon Barkley)

A bruiser in traffic and slippery in the open field

Has talent as a receiver and could make a living in the empty set or in the checkdowngame

Can become a number one RB if Aaron Jones does not re-sign

Feb 29, 2020; Indianapolis, Indiana, USA; Louisiana State Tigers linebacker Patrick Queen (LB32) runs the 40 yard dash during the 2020 NFL Combine at Lucas Oil Stadium. Brian Spurlock-USA TODAY Sports

College: LSU

Year: Junior

The inside linebacker out of Baton Rouge recorded 85 tackles with 12 of them being for a loss of yards. He also added three sacks to the Tigers historical run and an interception off of Tua Tagovailoa (Alabama QB) in the game of the year. The Packers have never had an inside linebacker that would stick around and Queen could finally fill that gap in Pettines defense.

Defensive MVP of The National Championship, Patrick Queen was able to lead his defense by calling every play. What really opens the Packers eyes is his aggressiveness when there is a ball carrier in sight. Also, Queen plays with a different type of swagger that would fit the Packers defense. His biggest impact on the Tigers defense was how well he covered the tight end in deep routes and mesh routes. He was also able to cover running backs in checkdown situations and blew up most screens in sight. Ex Packers Linebacker Blake Martinez struggled to cover tight ends on seam routes and had trouble picking up receivers over the middle. What would make Queen so special is he would be able to pick up on passing situations easily and has the intelligence to call the defense as a rookie. Also, with offensive lines and quarterbacks already focusing on how to contain the Smith brothers, this will give Queen a chance to make big plays in the backfield. The Packers past linebackers have always struggled against tight ends and picking up receivers on broken plays, so making the addition of Queen to Pettines defense will only make them more exciting to watch this season.

Recently the Packers were able to sign former Browns Linebacker Christian Kirksey, filling Blake Martinezs spot temporarily. Kirksey is a veteran who brings a lot of knowledge to the Packers defense. Kirksey is also known to be injury prone, playing only nine games for Cleveland last year. If the Packers draft Queen, he will be able to rotate with Kirksey and be able to gain knowledge from the veteran. Eventually Queen would prove himself and push out Christian Kirksey becoming a leader for the Packers young defense.

Intense hard hitting Linebacker

Able to cover receiving Running Backs and Tight Ends

Recognizes the screen well Plays with the Packers type of Swagger

Has experience being the Play caller already

Will have chances to make big plays with opposing teams fearing the Packers front.

Charlie Neibergall/Associated Press

College: Boise State

Year: Junior

The junior tackle out of Boise is an athletic big man that played every game since 2017 and also ran a 4.93 at the NFL Combine. He is able to move quickly to the block and does the best in pass protection. He does well in the run game when sealing off blocks that open up holes that can provide a spark to the Jones/Williams backfield.

Erza Cleveland is a quick guy who produced a lot of open holes for the run game at Boise State. He has quick feet making him able to seal off fast linebackers and defensive ends. In the run protection he is best on stretch plays because of his quickness and his ability to reach for a block. Cleveland also is able to play both left and right tackles which fits with the Packers history of producing versatile linemen. It seems that Cleveland might be a work in progress forthe first year or so because he would need to put some weight and muscle tone on giving him a stockier build giving him an advantage at being able to protect the inside run. Cleveland may be a bridge at first, but has the athletic ability to soon fill for the loss of Bryan Bulaga.

Recently, the Packers lost long time veteran, Bryan Bulaga, to the Chargers. Bulaga was able to protect Rodgers when All-Pro defensive ends would line up on the other side. He was able to shut down defensive ends Von Miller and Bradley Chubb, who were quick players that easily got after the quarterback. Rick Wagner of the Detroit Lions will be replacing Bulaga and will have to fill a big role. Cleveland would be able to prove himself in the preseason by beating out Wagner and becoming that quick lineman that can keep up with all these fast moving defensive ends and outside linebackers. He will also be successful because the Packers like to run toss/stretch plays where it will be easy for him to get out of his stance and go make a block up the field. The same thing applies for when they run screens with Davante Adams and Aaron Jones.

Agile

Quick feet and able to seal blocks to make holes for the running back

Will thrive in Outside zone runs and screens passes Quick enough to keep up with fast defensive linemen

Will have to put more weight on to be able to have a wide base in the Inside Runprotection

Can be a starter to fill Bulagas role

Related

See the article here:
3 Out of the Box First Round Choices To Improve The Packers - Total Packers

Karyopharm Announces Dosing of First Patient in Randomized Study Evaluating Low Dose Selinexor in Patients with Severe COVID-19 – Yahoo Finance

Posted: April 20, 2020 at 9:51 pm

NEWTON, Mass., April 20, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (KPTI) today announced dosing of the first patient in a randomized Phase 2 clinical study evaluating low dose oral selinexor in hospitalized patients with severe COVID-19. This global study is expected to enroll approximately 230 patients at clinical sites in the U.S., Europe, and Israel. Selinexor is an oral selective inhibitor of nuclear export (SINE) compound which blocks the cellular protein XPO1 which is involved in both the replication of SARS-CoV-2, the virus that causes COVID-19, and in the inflammatory response to the virus.

The randomized, multi-center, placebo-controlled Phase 2 study (XPORT-CoV-1001/NCT04349098) of low dose selinexor is designed to assess the activity and safety of 20mg of selinexor given orally three times a week for two weeks. Patients tolerating therapy well and experiencing clinical benefit may be eligible to continue treatment for an additional two weeks at the discretion of the treating physician. The primary endpoint of the study is time to clinical improvement based on improvement in the Ordinal Scale, consistent with the COVID-19 trial recommendations by the World Health Organization and the U.S. Food and Drug Administration (FDA). Additional secondary endpoints in the study include the overall death rate at day 28 as well as the rate of, and time to, mechanical ventilation.

In less than two weeks since announcing our intention to study selinexor in patients with severe COVID-19, we have quickly mobilized our team to activate clinical trial sites across the globe and are proud to announce the dosing of the first patient in our randomized study, said Sharon Shacham, PhD, MBA, President and Chief Scientific Officer of Karyopharm. This important milestone marks the first study of an XPO1 inhibitor in patients with severe viral infections. We remain highly encouraged by the potential anti-viral and anti-inflammatory activity of XPO1 inhibition with selinexor and look forward to working with the medical community of regulators, treating physicians and patients on advancing this important study as quickly as possible.

SINE compounds have been identified as having the potential to interfere with key host protein interactions with influenza, RSV and other viruses including SARS-CoV-2.1 Furthermore, XPO1 (also called CRM1) was identified as one of the host proteins with the highest number of functional connections with SARS-CoV proteins.2 Finally, SINE compounds, including selinexor, have demonstrated potent anti-inflammatory activity through the inhibition of Nuclear Factor kB (NF-kB), leading to reductions in cytokines such as IL6, IL1, IFNg and others in a variety of models, which may be particularly beneficial to hospitalized patients with COVID-19 and other severe viral infections.

In my laboratory, we have now used two different approaches to investigate selinexors ability to inhibit the viral propagation of the SARS-CoV-2 virus in Vero cells, which are monkey cells commonly used in modeling human viral infections. In our first experiment, with the assistance of Jackelyn Murray in my lab, we demonstrated that selinexor inhibited the production of new virus by 90% at a low concentration (100 nM) from cells that were already infected with SARS-CoV2. This is very exciting as low oral doses of selinexor are expected to deliver levels over 300 nM. In the second experiment, we showed that even lower levels of selinexor, only 10nM, could reduce the ability of the virus to infect new cells by about 99%. I am highly encouraged by these results and thrilled to see how quickly Karyopharm is able to test these scientific findings in patients so dramatically impacted by the current COVID-19 pandemic, said Ralph Tripp, PhD, a Georgia Research Alliance Eminent Scholar and Professor in the Department of Infectious Diseases in the College of Veterinary Medicine at the University of Georgia.

Selinexor, marketed as XPOVIO, is currently approved at higher doses by the FDA as a treatment for patients with relapsed or refractory multiple myeloma. Selinexor is currently the only XPO1 inhibitor approved for commercial use by the FDA and has been extensively tested in clinical trials across numerous cancer indications worldwide since 2012. Karyopharm has sufficient supply of selinexor for current and expected commercial patients with multiple myeloma, for ongoing clinical trials in patients with various cancers, as well as for this study in patients with COVID-19.

About XPOVIO (selinexor)

XPOVIO is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein exportin 1 (XPO1, also called CRM1). XPOVIO blocks the nuclear export of tumor suppressor, growth regulatory and anti-inflammatory proteins, leading to accumulation of these proteins in the nucleus and enhancing their anti-cancer activity in the cell. The forced nuclear retention of these proteins can counteract a multitude of the oncogenic pathways that, unchecked, allow cancer cells with severe DNA damage to continue to grow and divide in an unrestrained fashion. Karyopharm received accelerated U.S. Food and Drug Administration (FDA) approval of XPOVIO in July 2019 in combination with dexamethasone for the treatment of adult patients with relapsed refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. Karyopharm has also submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) with a request for conditional approval of selinexor. A supplemental New Drug Application was recently accepted by the FDA seeking accelerated approval for selinexor as a new treatment for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), and selinexor has received Fast Track and Orphan designation and Priority Review from the FDA with a scheduled PDUFA date of June 23, 2020 for this patient population. Selinexor is also being evaluated in several other mid-and later-phase clinical trials across multiple cancer indications, including in multiple myeloma in a pivotal, randomized Phase 3 study in combination with Velcade (bortezomib) and low-dose dexamethasone (BOSTON), for which Karyopharm announced positive top-line results in March 2020. Additional, ongoing trials for selinexor include as a potential backbone therapy in combination with approved myeloma therapies (STOMP), in liposarcoma (SEAL) and in endometrial cancer (SIENDO), among others. Additional Phase 1, Phase 2 and Phase 3 studies are ongoing or currently planned, including multiple studies in combination with approved therapies in a variety of tumor types to further inform Karyopharms clinical development priorities for selinexor. Additional clinical trial information for selinexor is available at http://www.clinicaltrials.gov.

For more information about Karyopharms products or clinical trials, please contact the Medical Information department at:

Tel: +1 (888) 209-9326Email: medicalinformation@karyopharm.com

IMPORTANT SAFETY INFORMATION

Thrombocytopenia

XPOVIO can cause thrombocytopenia, leading to potentially fatal hemorrhage. Thrombocytopenia was reported as an adverse reaction in 74% of patients, and severe (Grade 3-4) thrombocytopenia occurred in 61% of patients treated with XPOVIO. The median time to onset of the first event was 22 days. Bleeding occurred in 23% of patients with thrombocytopenia, clinically significant bleeding occurred in 5% of patients with thrombocytopenia and fatal hemorrhage occurred in <1% of patients.

Monitor platelet counts at baseline, during treatment, and as clinically indicated. Monitor more frequently during the first two months of treatment. Institute platelet transfusion and/or other treatments as clinically indicated. Monitor patients for signs and symptoms of bleeding and evaluate promptly. Interrupt and/or reduce dose, or permanently discontinue based on severity of adverse reaction.

Neutropenia

XPOVIO can cause neutropenia, potentially increasing the risk of infection. Neutropenia was reported as an adverse reaction in 34% of patients, and severe (Grade 3-4) neutropenia occurred in 21% of patients treated with XPOVIO. The median time to onset of the first event was 25 days. Febrile neutropenia was reported in 3% of patients.

Obtain neutrophil counts at baseline, during treatment, and as clinically indicated. Monitor more frequently during the first two months of treatment. Monitor patients for signs and symptoms of concomitant infection and evaluate promptly. Consider supportive measures including antimicrobials for signs of infection and use of growth factors (e.g., G-CSF). Interrupt and/or reduce dose, or permanently discontinue based on severity of adverse reaction.

Gastrointestinal Toxicity

Gastrointestinal toxicities occurred in patients treated with XPOVIO.

Nausea/Vomiting

Nausea was reported as an adverse reaction in 72% of patients, and Grade 3 nausea occurred in 9% of patients treated with XPOVIO. The median time to onset of the first nausea event was 3 days.

Vomiting was reported in 41% of patients, and Grade 3 vomiting occurred in 4% of patients treated with XPOVIO. The median time to onset of the first vomiting event was 5 days.

Provide prophylactic 5-HT3 antagonists and/or other anti-nausea agents, prior to and during treatment with XPOVIO. Manage nausea/vomiting by dose interruption, reduction, and/or discontinuation. Administer intravenous fluids and replace electrolytes to prevent dehydration in patients at risk. Use additional anti-nausea medications as clinically indicated.

Diarrhea

Diarrhea was reported as an adverse reaction in 44% of patients, and Grade 3 diarrhea occurred in 6% of patients treated with XPOVIO. The median time to onset of diarrhea was 15 days.Manage diarrhea by dose modifications and/or standard anti-diarrheal agents; administer intravenous fluids to prevent dehydration in patients at risk.

Anorexia/Weight Loss

Anorexia was reported as an adverse reaction in 53% of patients, and Grade 3 anorexia occurred in 5% of patients treated with XPOVIO. The median time to onset of anorexia was 8 days.

Weight loss was reported as an adverse reaction in 47% of patients, and Grade 3 weight loss occurred in 1% of patients treated with XPOVIO. The median time to onset of weight loss was 15 days.

Monitor patient weight at baseline, during treatment, and as clinically indicated. Monitor more frequently during the first two months of treatment. Manage anorexia and weight loss with dose modifications, appetite stimulants, and nutritional support.

Hyponatremia

XPOVIO can cause hyponatremia; 39% of patients treated with XPOVIO experienced hyponatremia, 22% of patients experienced Grade 3 or 4 hyponatremia. The median time to onset of the first event was 8 days.

Monitor sodium level at baseline, during treatment, and as clinically indicated. Monitor more frequently during the first two months of treatment. Correct sodium levels for concurrent hyperglycemia (serum glucose >150 mg/dL) and high serum paraprotein levels. Treat hyponatremia per clinical guidelines (intravenous saline and/or salt tablets), including dietary review. Interrupt and/or reduce dose, or permanently discontinue based on severity of adverse reaction.

Infections

In patients receiving XPOVIO, 52% of patients experienced any grade of infection. Upper respiratory tract infection of any grade occurred in 21%, pneumonia in 13%, and sepsis in 6% of patients. Grade 3 infections were reported in 25% of patients, and deaths resulting from an infection occurred in 4% of patients. The most commonly reported Grade 3 infections were pneumonia in 9% of patients, followed by sepsis in 6%. The median time to onset was 54 days for pneumonia and 42 days for sepsis. Most infections were not associated with neutropenia and were caused by non-opportunistic organisms.

Neurological Toxicity

Neurological toxicities occurred in patients treated with XPOVIO.

Neurological adverse reactions including dizziness, syncope, depressed level of consciousness, and mental status changes (including delirium and confusional state) occurred in 30% of patients, and severe events (Grade 3-4) occurred in 9% of patients treated with XPOVIO. Median time to the first event was 15 days.

Optimize hydration status, hemoglobin level, and concomitant medications to avoid exacerbating dizziness or mental status changes.

Embryo-Fetal Toxicity

Based on data from animal studies and its mechanism of action, XPOVIO can cause fetal harm when administered to a pregnant woman. Selinexor administration to pregnant animals during organogenesis resulted in structural abnormalities and alterations to growth at exposures below those occurring clinically at the recommended dose.

Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential and males with a female partner of reproductive potential to use effective contraception during treatment with XPOVIO and for 1 week after the last dose.

ADVERSE REACTIONSThe most common adverse reactions (incidence 20%) are thrombocytopenia, fatigue, nausea, anemia, decreased appetite, decreased weight, diarrhea, vomiting, hyponatremia, neutropenia, leukopenia, constipation, dyspnea, and upper respiratory tract infection.

The treatment discontinuation rate due to adverse reactions was 27%; 53% of patients had a reduction in the XPOVIO dose, and 65.3% had the dose of XPOVIO interrupted. The most frequent adverse reactions requiring permanent discontinuation in 4% or greater of patients who received XPOVIO included fatigue, nausea, and thrombocytopenia. The rate of fatal adverse reactions was 8.9%.

Please see XPOVIO Full Prescribing Information available atwww.XPOVIO.com.

References

1 Gordon, D. et al. A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug Repurposing. bioRxiv. 2020. 03.22.002386. https://doi.org/10.1101/2020.03.22.002386

2 Zhou, Y. et al. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discovery. 2020. 6:14. https://doi.org/10.1038/s41421-020-0153-3

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharms lead compound, XPOVIO (selinexor), received accelerated approval from the U.S. Food and Drug Administration (FDA) in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency. A supplemental New Drug Application was recently accepted by the FDA seeking accelerated approval for selinexor as a new treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. For more information, please visit http://www.karyopharm.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Karyopharms expectations and plans relating to selinexor as a potential treatment for hospitalized patients with severe COVID-19; the design and execution of a global randomized clinical trial to study this potential application of selinexor, including the dosing regimen; the potential anti-viral and anti-inflammatory properties of selinexor; submissions to, and the review and potential approval of selinexor in this indication by, regulatory authorities, including the anticipated availability of data to support such submissions, timing of such submissions and actions by regulatory authorities and the potential availability of accelerated approval pathways; the sufficiency of selinexor supply for commercial demand and clinical trial use; and the therapeutic potential of and potential clinical development plans for Karyopharms drug candidates, including the impact of a selinexor clinical trial on the timing or prioritization of other key company milestones, such as its expected submission of a supplemental new drug application in the second quarter of 2020 for XPOVIO in combination with once-weekly Velcade and low dose dexamethasone. Such statements are subject to numerous important factors, risks and uncertainties, many of which are beyond Karyopharm's control, that may cause actual events or results to differ materially from Karyopharm's current expectations. For example, there can be no guarantee that Karyopharm will successfully complete necessary clinical development phases of selinexor in this indication; that data from a clinical trial of selinexor would support its use in treatment of hospitalized patients with severe COVID-19; that regulators will approve the use of selinexor in hospitalized patients with severe COVID-19, or that such approval will be made on an accelerated timeline. Further, there can be no guarantee that any positive developments in the development or commercialization of Karyopharms drug candidate portfolio will result in stock price appreciation. Managements expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: the risk that the COVID-19 pandemic could disrupt Karyopharms business more severely than it currently anticipates, including by reducing sales of XPOVIO, interrupting or delaying research and development efforts, impacting the ability to procure sufficient supply for the development and commercialization of selinexor or other product candidates, delaying ongoing or planned clinical trials, impeding the execution of business plans, planned regulatory milestones and timelines, or inconveniencing patients; the adoption of selinexor for treatment of COVID-19 in the commercial marketplace, the timing and costs involved in commercializing selinexor for such indication or any of Karyopharms drug candidates that receive regulatory approval; the ability to retain regulatory approval of selinexor for such indication or any of Karyopharms drug candidates that receive regulatory approval; Karyopharm's results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies, including with respect to the need for additional clinical studies; the ability of Karyopharm or its third party collaborators or successors in interest to fully perform their respective obligations under the applicable agreement and the potential future financial implications of such agreement; Karyopharm's ability to obtain and maintain requisite regulatory approvals and to enroll patients in its clinical trials; unplanned cash requirements and expenditures; development of drug candidates by Karyopharms competitors for indications in which Karyopharm is currently developing its drug candidates; and Karyopharms ability to obtain, maintain and enforce patent and other intellectual property protection for any drug candidates it is developing. These and other risks are described under the caption "Risk Factors" in Karyopharms Annual Report on Form 10-K for the year ended December 31, 2019, which was filed with the Securities and Exchange Commission (SEC) on February 26, 2020, and in other filings that Karyopharm may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by law, Karyopharm expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Velcade is a registered trademark of Takeda Pharmaceutical Company Limited.

Contacts:

Investors: Karyopharm Therapeutics Inc. Ian Karp, Vice President, Investor and Public Relations857-297-2241 | ikarp@karyopharm.com

Media:

FTI ConsultingSimona Kormanikova or Robert Stanislaro212-850-5600 |Simona.Kormanikova@fticonsulting.com or robert.stanislaro@fticonsulting.com

View post:
Karyopharm Announces Dosing of First Patient in Randomized Study Evaluating Low Dose Selinexor in Patients with Severe COVID-19 - Yahoo Finance

MCU: 10 Ways Thor Changed Throughout The Movies | ScreenRant – Screen Rant

Posted: April 20, 2020 at 9:51 pm

Thor has easily become many people's favorite Avenger, even if he didn't originally start out that way.Thor has changed a lot as a character over the course of the MCU and has gone through significant developments, especially in his last three film appearances alone.

RELATED:Thor's 10 Best Fights In The MCU

Some of the changes have been minor and others major. One thing is for certain, he is a much different character than when he first appeared in Thor back in 2011.

Thor has gone through a lot of physical changes in the MCU and one of the most interesting being the loss of his eye. During his battle against Helain Thor: Ragnarok, Thor has his right eye slashed out. At the end ofthe movie,he's sporting an eyepatch making him lookvery similar to his father, Odin. The following year, during Avenger: Infinity War, he receives a replacement eye from Rocket with the only noticeable difference between the two being that his new eye is hazel as opposed to his natural iris color of blue.

One of the saddest and most beautiful moments in the MCU was Frigga's funeral in Thor: The Dark Worldafter she waskilled while attempting to protect Jane Foster. When he lost his mother, Thor was devastated but unfortunately, she was only the first of the many friends and family thathe would lose. Odin faded away in Ragnarok, The Warriors 3 were killed almost instantly by Hela upon her arrival,Thorwas forced to kill his sister in order to save his people,Loki was killed at the hand of Thanos during the opening scene ofInfinity War and to make matters worse during the same scene, he also loses Heimdall. With all the loss he has experienced, it's surprising that he has somehow managed to continue to fight.

Another devastating moment for Thor was when his hammer,Mjolnir, was destroyed by Hela in Ragnarok. Although he learned the lesson that he didn't need a hammer since his power was already apart of him, it is always better to have a weapon of some sort.

RELATED:MCU: 10 People Thor Should Have Been With Other Than Jane Foster

After realizing that he would need a new weapon in order to even stand a chance at defeating Thanos in Infinity War, He,Rocket, and Groot travel to have the ax called "Stormbreaker" forged,leading to the epic scene which sees the God of Thunder take on the full force of a dying star in order to form the metal and thewooden handle being provided by Groot.

Something Ragnarok did better than the other Thor movies was give him a strong arc. Throughout the film hestruggles with his abilities after losing Mjolnir.Aftera touching scene in which Odin comes to him in a vision and asks if he'sthe "God of Hammers",he realizesthat his strength didn't come from hisweapon but from inside him. The display of his true strength comes during the epic fight on the rainbow bridge in which he completely demolishes Hela's army of the dead without anytoolaiding him.

When the Avengers decided in Endgame that they were going to need to put the team back together in order to properly pull off the time heist to retrieve the Infinity Stones from the past, Rocket and Hulk were tasked with traveling to New Asgard to retrieve him. However, they quickly notice that he's gained a significant amount of weight over the 5-year gap likely due to all the beer he had been drinking. Thor's weight gain, despite being the source of some of the film's comedy, was used as a physical representation of the character's depression and guilt that came after feeling the effects of Thanos' snap.

The first and second Thor movies put part of the focus on the relationship between Thor and Jane, so it was surprising that the character was completely absent in Ragnarok, with Thor saying that they've broken up off-screen.It even became a joke during a scene in Endgame in which Thor is discussing during the events of Thor: The Dark World and extracting the Aether from Jane. Jane has been confirmed to return in Thor: Love and Thunder as the Mighty Thor, sothere is a chance we will see the relationship rekindled.

Although the first two Thor movies had their share of comedic moments, lots of the comedy from the first film coming from him being a fish-out-of-water on Earth, trying to adapt and understand human customs and the second had the majority of the comedic beats coming from characters like Darcy and Selvig. After seeing the lackluster fan reception to thosefilms, Marvel decided to take him in a new direction.

RELATED:10 Thor Mannerisms From The Comics Chris Hemsworth Nails

Thanks to Taika Waititi's more improvisational comedic style, the character wasway morehumorous in Ragnarok,making it more similar in tone to Guardians of the Galaxywhich is likely why he blended soseamlessly with those characters in Avengers: Infinity War.

In Ragnarok, Thor realized that the only way to save Asgard from Hela was to destroy it, which meant saying goodbye to the realm forever. In the end, Thor learnsthat the physical location wasn't what was important but rather the people that made it up. The film ends with the citizens boarding a ship in order to escape the destruction and heading off in the direction of Earth.

In Endgame, Thor has established New Asgard on Earth inTnsberg, Norway. Despite the move being unplanned, the new location for the Asgardian's home wasn't chosen at random. Often regarded as the oldest town in Norway,Tnsberg has played a role in the MCU before with it being the location where the Frost Giants arrived centuries agoand is also where Odin spent his final moments before his death.

At the end ofEndgame, after a heartfelt goodbye in which heappointsValkyrie to the mantle on King of New Asgard, Thorboards the Benatar with the rest of the Guardians of the Galaxy. Ever since audiences saw himinteract with theteam in Infinity War, they have been asking for more and the ending of the Endgame, especially Thor referring to them as the Asgardians of the Galaxy, seemingly confirms thatwill be in Phase 4 of the MCU. While it is unclear how long Thor will be a member for, some of Guardians have even been confirmed to show up in his 4th solo movie, Thor: Love and Thunder.

Thor's longgolden hair had become a staple of the character, so it was surprising when, like many things inRagnarok, he was forced to give it up. Before his gladiatorial match on Sakaar, he wasordered by the Grandmaster to have his hair cut in a hilariousscenefeaturing one of Stan Lee's funniest cameos as Thor's barber with a metal hand made of varying blades. While the end result ended up looking pretty good, Thor later allowed his hair to get long again during theBlip, so it is unclear if he would return to the look going forward.

NEXT:MCU: 10 Worst Decisions Thor Has Made

Next10 Obscure (But Awesome) Sci-Fi Movies You can Stream Today On Amazon Prime

Wesley Bell is a writer based out of Silver Spring, MD. He has a passion for film, art, music and all other forms of artistic expression. When he is not spending his time writing, he enjoys watching tv and movies.

See the article here:
MCU: 10 Ways Thor Changed Throughout The Movies | ScreenRant - Screen Rant

Insights into the Worldwide HRT Industry to 2027 – Featuring Abbott Laboratories, Novartis & Pfizer Among Others – ResearchAndMarkets.com -…

Posted: April 20, 2020 at 9:50 pm

DUBLIN--(BUSINESS WIRE)--The "Hormone Replacement Therapy Market Size, Share & Trends Analysis Report by Product (Estrogen, Human Growth), by Route Of Administration (Oral, Parenteral), by Type Of Disease, by Region, and Segment Forecasts, 2020 - 2027" report has been added to ResearchAndMarkets.com's offering.

The global hormone replacement therapy market size is expected to reach USD 39.6 billion by 2027, expanding at a CAGR of 7.7%. A significant rise in the incidence rate of hormonal disorders in the newborns, adults, and elderly and populations is driving the market. The Prader-Willi syndrome (PWS) affects one in every 15,000 newborns, thereby boosting the demand for the therapy.

Estrogen replacement hormone therapy helps in reducing the vaginal indications of menopause, such as dryness, burning, itching, and pain during intercourse. Estrogen is available in the forms of pill, gel, skin patch, cream or spray form. It is highly successful for treating problematic menopausal night sweats and hot flashes. Around 45% of women between the ages of 40 to 60 years of age were reported taking counseling sessions from a physician regarding the advantages and disadvantages of using hormone replacement therapy (HRT) after menopause.

Growing awareness about menopausal signs and the treatment options is growing the HRT market. Owing to the significant development for ERT, there has been an initiation of very safe treatment options for the patients situated in various geographies of the world. For example, augmentation of innovative drug delivery systems like transdermal estrogen patches and vaginal estrogen drugs.

Further key findings from the report suggest:

Key Topics Covered:

1. Methodology and Scope

2. Executive Summary

2.1 Market Outlook

2.2 Segment Outlook

2.2.1 Product

2.2.2 Route of Administration

2.2.3 Type of Disease

2.2.4 Region

2.3 Competitive Insights

3. Market Variables, Trends & Scope

3.1 Market Segmentation

3.2 Penetration & Growth Prospect Mapping

3.2.1 Market Driver Analysis

3.2.2 Market Restraint Analysis

3.3 Hormone Replacement Therapy Market: Business Environment Analysis Tools

3.3.1 Porter's Five Forces Analysis

3.3.2 PESTEL Analysis

4. Hormone Replacement Therapy Market: Product Analysis

4.1 Hormone Replacement Therapy Product Market Share Analysis, 2019 & 2027

4.2 Hormone Replacement Therapy Product Market: Segment Dashboard

4.3 Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the Product Segment

4.3.1 Estrogen Hormone Replacement Therapy

4.3.2 HGH Replacement Therapy

4.3.3 Thyroid Hormone Replacement Therapy

4.3.4 Testosterone Hormone Replacement Therapy

5. Hormone Replacement Therapy Market: Route of Administration Analysis

5.1 Hormone Replacement Therapy Route of Administration Market Share Analysis, 2019 & 2027

5.2 Hormone Replacement Therapy Route of Administration Market: Segment Dashboard

5.3 Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the Route of Administration Segment

5.3.1 Oral

5.3.2 Parenteral

5.3.3 Transdermal

5.3.4 Others

6. Hormone Replacement Therapy Market: Type of Disease Analysis

6.1 Hormone Replacement Therapy Type of Disease Market Share Analysis, 2019 & 2027

6.2 Hormone Replacement Therapy Type of Disease Market: Segment Dashboard

6.3 Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the Type of Disease Segment

6.3.1 Menopause

6.3.2 Hypothyroidism

6.3.3 Male Hypogonadism

6.3.4 Growth Hormone Deficiency

6.3.5 Others

7. Hormone Replacement Therapy Market: Regional Analysis

7.1 Hormone Replacement Therapy Regional Market Share Analysis, 2019 & 2027

7.2 Hormone Replacement Therapy Regional Market: Segment Dashboard

7.3 Regional Market Snapshot (Market Size, CAGR, Top Verticals, Key Players, Top Trends)

7.4 Market Size, & Forecasts, and Trend Analysis, 2016 to 2027

7.4.1 North America

7.4.2 Europe

7.4.3 Asia Pacific

7.4.4 Latin America

7.4.5 Middle East and Africa (MEA)

8. Competitive Analysis

8.1 Strategic Framework/ Competition Categorization (Key innovators, Market leaders, emerging players

8.2 Vendor Landscape

8.3 Company market position analysis (Geographic Presence, Product Portfolio, Strategic Initiatives, Employee Strength)

8.4 Company Profiles

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/rowxnu

See the rest here:
Insights into the Worldwide HRT Industry to 2027 - Featuring Abbott Laboratories, Novartis & Pfizer Among Others - ResearchAndMarkets.com -...

Ask the doctor: Is there anything I can do to prevent osteoporosis? – Independent.ie

Posted: April 20, 2020 at 9:50 pm

Q I am a healthy woman in my late 30s. My mother was recently diagnosed with osteoporosis at 68 years old. She is not surprised as her mother had a hump on her upper back and always complained of back pain, so we suspect she had it too. What can I do to keep myself from getting it? I have two young children and wonder if there is anything I should be doing for them?

A Bone is an amazing organ that is both relatively strong and light-weight. Bone has a complex internal and external structure. Internally, it consists of a honeycomb-like flexible matrix that account for about 30pc of internal bone. Bone tissue is continually undergoing remodelling due to the activity of various bone cells (e.g. osteoclasts, osteoblasts, osteocytes) and under the influence of many hormones and other important regulatory molecules (e.g. calcium, vitamin D, cytokines, growth factors). It is bone mineralisation that gives bone its rigidity.

Bone mass peaks around 16-25 years of age. This is one of the many reasons why children need to have healthy balanced diets and be engaged in plenty of exercise, particularly weight-bearing activities like tennis, gymnastics, soccer etc. This will help them achieve their maximum bone density before full skeletal maturity occurs. The recommended amount of weight-bearing exercise to prevent bone loss is 60 minutes per day for children and 30 minutes per day for adults.

Thereafter, we enter that gradual decline phase in life, including gradual bone density loss. From about 35 years onwards, it is estimated that bone mass decreases by 0.3pc to 0.5pc per year. From 6-10 years post menopause, bone loss decreases even further by 2pc-3pc per year for women (not on any treatment), partly due to the loss of oestrogen. That is why Hormone Replacement Therapy (HRT) can be used to treat osteoporosis. Healthy women, without risk factors, taking HRT need not worry about osteoporosis screening until they decide to stop taking it.

Osteoporosis is a common disease that is characterised by low bone mass, microarchitectural disruption and skeletal fragility, making your bones more easy to break or fracture. The prevalence of osteoporosis is higher in white/fair-skinned people.

Risk factors for osteoporosis include: advancing age, previous low-trauma fracture, long-term oral steroid treatment, parental history of hip fracture or osteoporosis, low body weight (Body Mass Index less than 19kg/m2), current cigarette smoking, rheumatoid arthritis and excessive alcohol consumption (more than three units per day). Excessive alcohol may cause dietary and liver problems and low levels of hormones, which can affect bone. Excessive caffeine consumption (more than 300mg-400mg per day) can also increase bone loss by increasing calcium excretion in urine, resulting in the body taking calcium from the bone.

Secondary causes of osteoporosis include: premature menopause (before 45 years old), low testosterone levels, inflammatory bowel disease, gastro-intestinal malabsorption syndromes like coeliac disease and chronic liver or kidney disease, past or present eating disorders. Being immobile, bedbound or wheelchair bound for six weeks or longer means you are unable to weight-bear. Bone loss occurs as your bones are not put under routine daily stress, which is necessary for bone remodelling in order to stay strong and healthy. Long-term use of certain medication can increase bone loss. Dietary deficiency of calcium, vitamin D or protein can increase bone loss.

What you can do to ensure optimal bone health at any age is two-fold. Firstly, assess your diet for your consumption of dairy products, which are one of the best sources of calcium, especially the fortified milks. Not only do they have calcium, but also have vitamin D. The best sources of calcium are milk, cheese and yoghurt. Bread, nuts and any oily fish (e.g. salmon, sardines, tuna) also contain calcium and vitamin D, as do some dark green vegetables.

Secondly, make sure you are getting regular weight-bearing exercise such as walking, hiking or any of those listed above.

Dr Jennifer Grant is a GP with the Beacon Hospital HealthCheck

Weekend Magazine

Excerpt from:
Ask the doctor: Is there anything I can do to prevent osteoporosis? - Independent.ie

Are Diets for Weight Loss Effective? Yes, But Theres a Catch – Runner’s World

Posted: April 20, 2020 at 9:48 pm

Claudia TotirGetty Images

When embarking on a weight loss journey, there are plenty of options when it comes to diets to follow, from Mediterranean and DASH approaches to keto and macro tracking. The biggest question: Which one should you follow? Recent research in The BMJ suggests it doesnt actually matter what diet you embrace, since most of them will provide resultsbut theres a catch.

Researchers compared 17 diets that were studied in 121 nutrition trials, totaling nearly 22,000 participants. They found that all diets had some effect on reducing weight and lowering blood pressure over the initial six months.

Low-carb and low-fat options had about the same modest results on weight, but the latter is slightly more beneficial in regards to blood pressure, the study noted. The diets with the most weight reduction were Atkins, DASH, and Zone, but none of the diets significantly improved levels of HDL (good) cholesterol.

The most notable conclusion, though, is that while most diets that changed macronutrient distributions showed some degree of weight loss and improvements in blood pressure at the six-month mark, those effects largely disappeared a year after the diets start.

Does this mean the takeaway here is that you shouldnt even give weight loss and blood pressure management a shot, since youll be back to square one anyway? Not at all, said Helen Truby, Ph.D., coauthor of an accompanying editorial on the study and director of nutrition and dietetics at Monash University in Australia.

Instead, she told Runners World, the message of this study should be that you could choose any popular diet and youll likely see results, but that after a certain period of timefor example, about six monthsthe focus should shift to weight maintenance.

[Stay injury free on the road by getting on the mat with Yoga for Runners.]

For instance, that might involve changing from a diet mindset into one focused more on long-term strategies, said Truby, particularly when it comes to nutrition. Considering that the Mediterranean model fared so well here, the researchers suggest that could be the eating plan with the most staying power in terms of maintaining weight loss and cardiovascular benefits.

National dietary guidelines in any country are failing to resonate with the public, Truby said, and this study shows that dietsand particularly those that have numerous restrictionsare less helpful in the long run than focusing on healthy eating basics like eating more vegetables, legumes, and whole grains, and limiting your amount of sugar, salt, and alcohol.

Read more here:
Are Diets for Weight Loss Effective? Yes, But Theres a Catch - Runner's World

Mediterranean diet linked to lower inflammation, healthy aging – Harvard Health

Posted: April 20, 2020 at 9:48 pm

Published: May, 2020

An anti-inflammation diet might help fight chronic disease, perhaps by changing the gut bacteria. In the past 20 years, research has discovered that the genes of bacteria that live in our gut (the gut microbiome) can affect our health. A study published Feb. 17, 2020, in the journal Gut compared the gut microbiome of about 600 older adults (ages 65 to 79) assigned to either a Mediterranean-style diet rich in fruits, vegetables, nuts, legumes, olive oil, and fish and low in red meat and saturated fats or to a regular diet. Many previous studies have found that people who regularly consume the Mediterranean diet have lower rates of bowel cancer, insulin resistance, fatty liver disease, and other diseases. The question this study addressed was whether these lower rates of disease might result from changes in the gut microbiome. Among people assigned to the Mediterranean diet, there was indeed reduced inflammation. In addition, the gut microbiome was changed in ways that previous studies have shown is associated with a lower risk of bowel cancer, insulin resistance, fatty liver disease, and cell damage, and associated with improved thinking skills. Finally, the gut microbiome reverted to a less healthy profile after people stopped the Mediterranean diet. Thus, the study suggests that the beneficial health effects of this diet may be due, in part, to changes in the gut microbiome.

Image: gbh007/Getty Images

Disclaimer:As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles. No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.

Excerpt from:
Mediterranean diet linked to lower inflammation, healthy aging - Harvard Health

Diet quality counts more than type of diet – Harvard Health

Posted: April 20, 2020 at 9:48 pm

Published: May, 2020

Simply following a low-carb or low-fat diet is less important than including high-quality healthy foods within those diets and the latter may help you live longer, says a recent study published online Jan. 21, 2020, by JAMA Internal Medicine. Researchers tracked deaths from all causes among 37,233 adults over a 15-year period. The study included data on the diets of people participating in the U.S. National Health and Nutrition Examination Survey. The diets were scored based on their specific types of fat, protein, and carbohydrates, which determined if people followed a primarily low-carb diet or low-fat diet and the quality of foods they ate.

The researchers found that there was no significant difference in death rates between the people in the low-fat or low-carb group whose diets emphasized high-quality foods (such as whole grains, non-starchy vegetables, whole fruits, and nuts). They also found risk of death to be the same for low-fat and low-carb eaters that included more unhealthy foods (such as red and processed meat, butter, refined grains, and added sugar). What did differ significantly was the higher likelihood of premature death in people with low food quality scores whether their diet was low fat or low carb.

Disclaimer:As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles. No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.

See the article here:
Diet quality counts more than type of diet - Harvard Health

The Top 20 Biggest Nutrition Myths – Healthline

Posted: April 20, 2020 at 9:48 pm

Scrolling through social media, reading your favorite magazine, or visiting popular websites exposes you to endless information about nutrition and health most of which is incorrect.

Even qualified health professionals, including doctors and dietitians, are to blame for spreading misinformation about nutrition to the public, adding to the confusion.

Here are 20 of the biggest myths related to nutrition, and why these antiquated beliefs need to be put to rest.

Though creating a calorie deficit by burning more energy than you take in is the most important factor when it comes to weight loss, its not the only thing that matters.

Relying solely on calorie intake doesnt account for the large number of variables that may prevent someone from losing weight, even when on a very low calorie diet.

For example, hormonal imbalances, health conditions like hypothyroidism, metabolic adaptations, the use of certain medications, and genetics are just some of the factors that may make weight loss harder for some people, even when theyre on a strict diet (1, 2).

This concept also fails to emphasize the importance of sustainability and diet quality for weight loss. Those following the calories in, calories out method typically concentrate solely on the calorie value of foods, not their nutrient value (3).

This can lead to choosing low calorie, nutrient-poor foods like rice cakes and egg whites over higher calorie, nutrient-dense foods like avocados and whole eggs, which isnt the best for overall health.

The calories in, calories out theory doesnt account for several variables that may prevent someone from losing weight. Many factors, such as genetics, medical conditions, and metabolic adaptations, make weight loss much harder for some.

Though this antiquated and incorrect theory is slowly being put to rest, many people still fear high fat foods and follow low fat diets in the hopes that cutting their fat intake will benefit their overall health.

Dietary fat is essential for optimal health. Plus, low fat diets have been linked to a greater risk of health issues, including metabolic syndrome, and may lead to an increase in insulin resistance and triglyceride levels, which are known risk factors for heart disease (4, 5).

Whats more, diets that are higher in fat have been proven just as effective or even more so than low fat diets when it comes to encouraging weight loss (6, 7).

Of course, extremes in either direction, whether it be a very low fat or very high fat diet, may harm your health, especially when diet quality is poor.

Many high fat foods are extremely nutritious and can help you maintain a healthy weight.

While it was once thought that eating breakfast was one of the most important factors in setting yourself up for a healthy day, research has shown that this might not be the case for most adults (8).

For instance, research indicates that forgoing breakfast may result in reduced calorie intake (9).

Moreover, partaking in intermittent fasting, during which breakfast is either skipped or consumed later in the day, has been linked to a plethora of benefits, including improved blood sugar control and reductions in inflammatory markers (10, 11, 12).

However, intermittent fasting can also be accomplished by consuming a regular breakfast then having your last meal earlier in the evening to maintain a fasting window of 1416 hours.

Keep in mind that this does not apply to growing children and teens or those with increased nutrient needs, such as pregnant women and those with certain health conditions, as skipping meals may lead to negative health effects in these populations (13, 14).

On the other hand, some evidence shows that eating breakfast and consuming more calories earlier in the day rather than at night, coupled with reduced meal frequency, may benefit health by reducing inflammation and body weight (15).

Regardless, if you enjoy breakfast, eat it. If youre not a breakfast person, dont feel the need to add it to your daily routine.

Eating breakfast is not necessary for everyone. Health benefits are associated with both eating breakfast and skipping it.

Eating small, frequent meals regularly throughout the day is a method used by many people to boost metabolism and weight loss.

However, if you are healthy, the frequency of your meals does not matter as long as you meet your energy needs.

That said, those with certain medical conditions, such as diabetes, coronary artery disease, and irritable bowel syndrome (IBS), as well as those who are pregnant, may benefit from eating more frequent meals.

Eating frequent meals throughout the day is not the best way to promote weight loss. Research shows that a regular meal pattern may be best for health.

The rising interest in low calorie, low carb, sugar-free foods has led to an increase in products that contain non-nutritive sweeteners (NNS). While its clear that a diet high in added sugar significantly increases disease risk, intake of NNS can also lead to negative health outcomes.

For example, NNS intake may increase your risk of type 2 diabetes by leading to negative shifts in gut bacteria and promoting blood sugar dysregulation. Whats more, regular NNS intake is associated with overall unhealthy lifestyle patterns (16, 17).

Keep in mind that research in this area is ongoing, and future high quality studies are needed to confirm these potential links.

Non-nutritive sweeteners may lead to adverse health outcomes, such as an increased risk of type 2 diabetes and negative changes to gut bacteria.

Although macro coaches may lead you to believe that the ratio of macronutrients in your diet is all that matters when it comes to weight loss and overall health, this narrow-minded take on nutrition is missing the bigger picture.

While tweaking macro ratios can benefit health in many ways, the most important factor in any diet is the quality of the foods you eat.

Though it may be possible to lose weight by eating nothing but highly processed foods and protein shakes, focusing solely on macronutrients discounts how eating certain foods can either increase or decrease metabolic health, disease risk, lifespan, and vitality.

Although tweaking macro ratios can be helpful in some ways, the most important way to promote overall health is to follow a diet rich in whole, unprocessed foods, regardless of the macro ratio.

Often labeled as unhealthy by those in the nutrition world, white potatoes are restricted by many people wanting to lose weight or improve their overall health.

While eating too much of any food including white potatoes can lead to weight gain, these starchy tubers are highly nutritious and can be included as part of a healthy diet.

White potatoes are an excellent source of many nutrients, including potassium, vitamin C, and fiber.

Plus, theyre more filling than other carb sources like rice and pasta and can help you feel more satisfied after meals. Just remember to enjoy potatoes baked or roasted, not fried (18, 19).

White potatoes are a nutritious carb choice just be sure to enjoy them in more healthful ways, such as roasted or baked.

Take a trip to your local grocery store and youll find a variety of products labeled diet, light, low fat, and fat-free. While these products are tempting to those wanting to shed excess body fat, theyre typically an unhealthy choice.

Research has shown that many low fat and diet items contain much more added sugar and salt than their regular-fat counterparts. Its best to forgo these products and instead enjoy small amounts of foods like full fat yogurt, cheese, and nut butters (20, 21).

Low fat and diet foods are typically high in sugar and salt. Unaltered higher fat alternatives are often a healthier choice.

While focusing on consuming a nutrient-dense, well-rounded diet is the most essential component of health, supplements when used correctly and in the right form can be beneficial in many ways.

For many, especially those with health conditions like type 2 diabetes, as well as those who take common medications like statins, proton pump inhibitors, birth control, and antidiabetic medications, taking specific supplements can significantly affect their health (22, 23, 24).

For example, supplementing with magnesium and B vitamins has been shown to benefit those with type 2 diabetes by enhancing blood sugar and reducing heart disease risk factors and diabetes-related complications (25, 26).

Those on restrictive diets, people with genetic mutations like methylenetetrahydrofolate reductase (MTHFR), people over the age of 50, and pregnant or breastfeeding women are other examples of populations that may benefit from taking specific supplements.

Supplements are useful and often necessary in many populations. The use of common medications, age, and certain medical conditions are just some of the reasons why supplements may be needed for some people.

While reducing calorie intake can indeed boost weight loss, cutting calories too low can lead to metabolic adaptations and long-term health consequences.

Though going on a very low calorie diet will likely promote rapid weight loss in the short term, long-term adherence to very low calorie diets leads to a reduction in metabolic rate, increased feelings of hunger, and alterations in fullness hormones (27).

This makes long-term weight maintenance difficult.

This is why studies have shown that low calorie dieters rarely succeed in keeping excess weight off in the long term (27).

Very low calorie diets lead to metabolic adaptations that make long-term weight maintenance difficult.

Obesity is associated with many health conditions, including type 2 diabetes, heart disease, depression, certain cancers, and even early death (28, 29).

Still, reducing your disease risk does not mean you have to be skinny. Whats most important is consuming a nutritious diet and maintaining an active lifestyle, as these behaviors often improve your body weight and body fat percentage.

Though obesity increases your risk of disease, you dont have to be skinny to be healthy. Rather, maintaining a healthy body weight and body fat percent by consuming a nutritious diet and maintaining an active lifestyle is most important.

Many people are told to pop calcium supplements to keep their skeletal system healthy. However, current research has shown that supplementing with calcium may do more harm than good.

For example, some studies have linked calcium supplements to an increased risk of heart disease. Additionally, research shows that they dont reduce the risk of fracture or osteoporosis (30, 31).

If youre concerned about your calcium intake, its best to focus on dietary sources of calcium like full fat yogurt, sardines, beans, and seeds.

Although medical professionals commonly prescribe calcium supplements, current research shows that these supplements may do more harm than good.

Many people struggle with getting adequate dietary fiber, which is why fiber supplements are so popular. Although fiber supplements can benefit health by improving bowel movements and blood sugar control, they should not replace real food (32).

High fiber whole foods like vegetables, beans, and fruit contain nutrients and plant compounds that work synergistically to promote your health, and they cant be replaced by fiber supplements.

Fiber supplements should not be used as a replacement for nutritious, high fiber foods.

Certain juices and smoothies are highly nutritious. For example, a nutrient-dense smoothie or freshly made juice composed primarily of non-starchy vegetables can be a great way to increase your vitamin, mineral, and antioxidant intake.

Yet, its important to know that most juices and smoothies sold at stores are loaded with sugar and calories. When consumed in excess, they can promote weight gain and other health issues like tooth decay and blood sugar dysregulation (33, 34, 35).

Many store-bought juices and smoothies are packed with added sugar and calories.

Probiotics are amongst the most popular dietary supplements on the market. However, practitioners generally overprescribed them, and research has demonstrated that some people may not benefit from probiotics like others do (36).

Not only are some peoples digestive systems resistant to probiotic colonization, but introducing probiotics through supplements may lead to negative changes in their gut bacteria.

Plus, bacterial overgrowth in the small intestine related to probiotic use can lead to bloating, gas, and other adverse side effects (37).

Additionally, some studies show that probiotic treatment following a course of antibiotics may delay the natural reconstitution of normal gut bacteria (38).

Instead of being prescribed as a one-size-fits-all supplement, probiotics should be more personalized and only be used when a therapeutic benefit is likely.

Current research suggests that probiotic supplements may not benefit everyone and should not be prescribed as a one-size-fits-all supplement.

Dont be fooled by the dramatic before and after pictures used by supplement companies and stories of rapid weight loss attained with little to no effort.

Weight loss is not easy. It requires consistency, self-love, hard work, and patience. Plus, genetics and other factors make weight loss much harder for some than others.

If youre struggling to lose weight, youre not alone. The best thing to do is drown out the weight loss noise that youre exposed to every day and find a nourishing and sustainable dietary and activity pattern that works for you.

Weight loss is difficult for most people and requires consistency, self-love, hard work, and patience. Many factors may influence how easy it is for you to lose weight.

Theres no need to obsess over your calorie intake and track every morsel of food that passes your lips to lose weight.

Although food tracking can be a useful tool when trying to lose excess body fat, its not right for everyone.

Whats more, being overly preoccupied with food by tracking calories has been associated with an increased risk of disordered eating tendencies (39).

Although tracking calories may help some people lose weight, its not necessary for everyone and may lead to disordered eating tendencies.

Cholesterol-rich foods have gotten a bad rap thanks to misconceptions about how dietary cholesterol affects heart health.

While some people are more sensitive to dietary cholesterol than others, overall, nutrient-dense, cholesterol-rich foods can be included in a healthy diet (40).

In fact, including cholesterol-rich, nutritious foods like eggs and full fat yogurt in your diet may boost health by enhancing feelings of fullness and providing important nutrients that other foods lack (41, 42, 43).

High cholesterol foods like eggs and full fat yogurt are highly nutritious. Although genetic factors make some people more sensitive to dietary cholesterol, for most people, high cholesterol foods can be included as part of a healthy diet.

Many people assume that eating disorders and disordered eating tendencies only affect women. In reality, adolescent and adult men are also at risk.

Whats more, over 30% of adolescent men in the United States report body dissatisfaction and the use of unhealthy methods to attain their ideal body type (44).

Its important to note that eating disorders present differently in men than women, and theyre more prevalent in adolescent and young adult men who are gay or bisexual, highlighting the need for eating disorder treatments that are better adapted to the male population (44, 45).

Eating disorders affect both men and women. However, eating disorders present differently in men than women, highlighting the need for eating disorder treatments that are better adapted to the male population.

Just as fat has been blamed for promoting weight gain and heart disease, carbs have been shunned by many people over fears that consuming this macronutrient will cause obesity, diabetes, and other adverse health effects.

In reality, eating a moderate amount of nutritious carbs that are high in fiber, vitamins, and minerals like starchy root vegetables, ancient grains, and legumes will likely benefit your health not harm it.

For example, dietary patterns that contain a balanced mix of high fiber carbs mainly from produce, healthy fats, and proteins, such as the Mediterranean diet, have been associated with a reduced risk of obesity, diabetes, certain cancers, and heart disease (46, 47).

However, carb-rich foods like cakes, cookies, sweetened beverages, and white bread should be restricted, as these foods can increase weight gain and disease risk when eaten in excess. As you can see, food quality is the main predictor of disease risk (48).

Including healthy carb choices in your diet wont make you gain weight. However, following unhealthy eating patters and overindulging in carb-rich sugary foods will lead to weight gain.

The nutrition world is rife with misinformation, leading to public confusion, mistrust of health professionals, and poor dietary choices.

This, coupled with the fact that nutrition science is constantly changing, makes it no wonder that most people have a warped view of what constitutes a healthy diet.

Although these nutrition myths are likely here to stay, educating yourself by separating fact from fiction when it comes to nutrition can help you feel more empowered to develop a nutritious and sustainable dietary pattern that works for your individual needs.

Originally posted here:
The Top 20 Biggest Nutrition Myths - Healthline


Page 826«..1020..825826827828..840850..»